inhibitor BEA409

Inhibitor BEA409 is a synthetic small molecule belonging to the class of n-acyl-alpha amino acids and derivatives. It was developed as an experimental inhibitor targeting HIV-1 protease. The compound features two central hydroxy groups that mimic the geminal hydroxy groups of a cleavage-reaction intermediate in the HIV-1 protease catalytic site. Structural studies have shown that these hydroxyls interact with the catalytic aspartic acid residues of HIV-1 protease and induce minor conformational changes in the enzyme-inhibitor complex. Inhibitor BEA409 has been used primarily for structural biology research to understand binding interactions and inhibitory mechanisms against HIV-1 protease[1][2][3][5].

Other names

N,N-[2,5-O-[DI-4-THIOPHEN-3-YL-BENZYL]-GLUCARYL]-DI-[VALYL-AMIDO-METHANE]N1,N6-bis[(1S)-2-Methyl-1-(methylcarbamoyl)propyl]-(2R,3R,4R,5R)-2,5-bis[4-(3-thienyl)benzyloxy]-3,4-dihydroxyhexanediamide